DDInter535 DDInter1329
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255
Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Propantheline
Propantheline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Diazoxide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Minoxidil
Minoxidil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Diazoxide {u} (Compound) binds {v} (Gene) CA1
CA1 {u} (Gene) is bound by {v} (Compound) Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Diazoxide {u} (Compound) binds {v} (Gene) ATP1A1
ATP1A1 {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Diazoxide {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Diazoxide {u} (Compound) binds {v} (Gene) GLUL
GLUL {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Diazoxide {u} (Compound) upregulates {v} (Gene) RBM6
RBM6 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Diazoxide {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is upregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Diazoxide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Minoxidil (Compound) and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Diazoxide (Compound) binds CA1 (Gene) and CA1 (Gene) is bound by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Oliceridine
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Diazoxide (Compound) binds ATP1A1 (Gene) and ATP1A1 (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Oliceridine
Diazoxide (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is bound by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Diazoxide (Compound) binds GLUL (Gene) and GLUL (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Diazoxide (Compound) upregulates RBM6 (Gene) and RBM6 (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Oliceridine
Diazoxide (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine